Financial Analysis: BeOne Medicines (NASDAQ:ONC) versus Aurinia Pharmaceuticals (NASDAQ:AUPH)

BeOne Medicines (NASDAQ:ONC) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations for BeOne Medicines and Aurinia Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1	1	11	2	2.93
Aurinia Pharmaceuticals	0	4	2	0	2.33

BeOne Medicines presently has a consensus price target of $390.00, suggesting a potential upside of 39.34%. Aurinia Pharmaceuticals has a consensus price target of $17.25, suggesting a potential upside of 0.12%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Aurinia Pharmaceuticals.

Insider & Institutional Ownership

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares BeOne Medicines and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

Valuation & Earnings

This table compares BeOne Medicines and Aurinia Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34 billion	5.75	$286.93 million	$4.47	62.62
Aurinia Pharmaceuticals	$283.05 million	7.83	$287.20 million	$2.17	7.94

Aurinia Pharmaceuticals has lower revenue, but higher earnings than BeOne Medicines. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Summary

BeOne Medicines beats Aurinia Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.